ATOSSA THERAPEUTICS, INC. (ATOS)

Insider Trading Filed: 2026-05-14

Key Insights

Director Chen Shu-Chih received a grant of 10,000 restricted stock units vesting on May 12, 2027, representing a $0 transaction price typical of equity compensation rather than open market purchases.
Chen maintains indirect beneficial ownership of 1,483 shares through Ensisheim Partners, LLC (shared with Dr. Steven C. Quay), indicating a modest overall equity stake in the company despite his director role.
This filing represents routine equity compensation to a company director with no material insider buying or selling activity, suggesting stable insider confidence but no significant new investment conviction.

Insider Trading Filed: 2026-05-14

Key Insights

Director Remmel H. Lawrence acquired 10,000 restricted stock units (RSUs) on May 12, 2026, vesting one year later, indicating company confidence in long-term value and insider alignment with shareholders.
The grant was at $0 price with zero consideration, representing compensation rather than market purchases, which is typical for director equity awards but shows no discretionary buying signal.
Lawrence's total beneficial ownership increased to 10,683 shares following this transaction, suggesting a relatively modest equity stake despite his director position at the company.

Insider Trading Filed: 2026-05-14

Key Insights

Director Jonathan Finn received a grant of 10,000 restricted stock units (RSUs) on May 12, 2026, vesting one year later, indicating continued equity compensation alignment with company performance.
Following this transaction, Finn's total beneficial ownership increased to 11,666 shares, demonstrating a meaningful insider stake in ATOS despite the relatively modest grant size.
The RSU grant at $0 exercise price represents a direct equity incentive rather than a market-based purchase, suggesting the company is using equity compensation as a retention mechanism for board members.

Insider Trading Filed: 2026-05-14

Key Insights

Director Stephen J. Galli acquired 10,000 restricted stock units (RSUs) on 05/12/2026 at no cost, representing a standard equity compensation grant with a one-year vesting schedule, indicating routine executive compensation rather than discretionary market purchases.
Following this transaction, Galli's total beneficial ownership increased to 10,006 shares, suggesting a relatively modest shareholding position for a director-level insider at the company.
The grant of RSUs with $0 exercise price and future vesting is a non-cash compensation arrangement common in biotech companies, which does not signal strong insider confidence in near-term stock appreciation but rather reflects standard equity incentive practices.

Insider Trading Filed: 2026-05-14

Key Insights

Director Tessa Cigler acquired 10,000 restricted stock units (RSUs) on May 12, 2026, with a grant price of $0, indicating a compensation grant rather than a market purchase.
The RSUs vest on the first anniversary of May 12, 2026, representing a one-year vesting schedule that aligns executive compensation with longer-term company performance.
This is a routine equity compensation transaction for a director, showing continued engagement with the company but providing no signal regarding insider confidence in near-term stock price movements.

Current Report Filed: 2026-05-08

Key Insights

Atossa announced Q1 2026 financial results on May 8, 2026, with the full press release details not provided in this 8-K excerpt, limiting ability to assess actual financial performance and operational metrics.
The filing is marked as non-material disclosure under Section 18, indicating the company views this earnings announcement as routine earnings communication rather than a material event requiring full liability exposure.
Filing was signed by Mark J. Daniel as CFO, confirming proper authorization and company responsiveness in timely disclosure of quarterly results to shareholders.

Quarterly Report Filed: 2026-05-08

Key Insights

Company executed a reverse stock split on February 2, 2026, indicating potential financial distress or efforts to maintain Nasdaq listing compliance requirements.
The filing shows multiple series of convertible preferred stock (Series A, B, and C) and warrants outstanding, suggesting significant dilution to common shareholders from prior financing rounds.
As a smaller reporting company and non-accelerated filer in the biotech sector, Atossa has reduced regulatory disclosure requirements, limiting transparency into R&D progress and clinical developments for investors.
The company maintains money market funds as fair value Level 1 and Level 2 assets, suggesting it still has some cash reserves, though the extent and runway are unclear from the truncated filing content.

Current Report Filed: 2026-05-08

Key Insights

All three Class II director nominees were successfully elected with solid support margins (66-87% approval), indicating stable board governance and shareholder confidence in current leadership.
Stockholders approved a reverse stock split authorization (2:1 to 20:1 ratio) with 56% voting in favor, suggesting the board may implement this to maintain Nasdaq listing compliance or improve share price perception.
The advisory vote on executive compensation passed with 77.5% approval despite 2.2M broker non-votes, demonstrating reasonable shareholder alignment with management pay practices.
Ernst & Young LLP was ratified as independent auditor with 90.2% approval and minimal opposition, reflecting confidence in financial reporting and audit oversight.

Current Report Filed: 2026-04-16

Key Insights

Atossa Therapeutics has resolved a patent dispute with Intas Pharmaceuticals and Jina Pharmaceuticals, which helps reduce uncertainty around its intellectual property portfolio.
The settlement agreement preserves Atossa's ability to continue developing and commercializing its lead drug candidate Z-endoxifen in key therapeutic areas like oncology, endocrine dysfunction, and muscular dystrophy.
Atossa's two patents related to endoxifen are expected to remain issued and fully enforceable against other third parties upon termination of the pending PTAB proceedings.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Steven C. Quay, who is the President and CEO of Atossa Therapeutics, Inc. (ATOS), acquired 65,000 shares of the company's common stock through a grant of restricted stock units (RSUs).
The number of securities reported has been adjusted to reflect a 1-for-15 reverse stock split that the company recently effected.
Quay also holds an indirect beneficial ownership of 1,483 shares of the company's common stock through his ownership of Ensisheim Partners, LLC.

Annual Report Filed: 2026-03-25

Key Insights

Atossa Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, providing an update on its financial performance and business operations.
The company reported an increase in research and development expenses, likely due to continued investment in its pipeline of therapeutic candidates.
Atossa Therapeutics disclosed several subsequent events, including an at-the-market offering and a reverse stock split, which may impact the company's capital structure and share price.

Current Report Filed: 2026-03-25

Key Insights

Atossa Therapeutics, Inc. reported its Q4 and full-year 2025 financial results, which could provide insights into the company's recent operational and financial performance.
The filing does not mention any material agreements, leadership changes, or other significant corporate events, suggesting a relatively routine quarterly update.
Investors should review the press release (Exhibit 99.1) for details on revenue, expenses, and any updates to the company's development pipeline or guidance.

Current Report Filed: 2026-02-20

Key Insights

Atossa Therapeutics entered into a $50 million at-the-market (ATM) equity offering program, allowing the company to issue and sell shares of its common stock from time to time.
The company terminated its prior $50 million ATM equity offering agreement with Jefferies LLC, as it did not undertake any sales under that agreement.
The company intends to use the proceeds from the new ATM offering for clinical development, working capital, and general corporate purposes, potentially including licensing, acquisition, or investment in complementary businesses.

Current Report Filed: 2026-02-11

Key Insights

The company issued its 2026 Letter to Shareholders, providing investors with an update on its business and operations.
The letter likely contains information on the company's financial performance, key initiatives, and strategic priorities for the year ahead.
Investors should review the letter for any material developments or changes that could impact the company's future prospects.

Current Report Filed: 2026-01-26

Key Insights

Atossa Therapeutics, Inc. approved a 15:1 reverse stock split of its common stock, effective February 2, 2026, to maintain its listing on the Nasdaq Stock Market.
The reverse stock split will proportionately adjust the number of shares subject to outstanding equity awards and the conversion price of the company's Series B Convertible Preferred Stock.
Stockholders approved the reverse stock split proposal at the company's Special Meeting of Stockholders held on January 20, 2026.

Insider Trading Filed: 2026-01-22

Key Insights

The CEO of Atossa Therapeutics, Inc. (ATOS) acquired a significant number of 325,203 shares of the company's common stock, indicating their confidence in the company's future prospects.
The CEO was also granted 950,000 stock options with an exercise price of $0.603, suggesting potential upside for the company's share price.
The CEO holds a significant ownership stake in the company, both directly and indirectly through their ownership in Ensisheim Partners, LLC, aligning their interests with those of other shareholders.

Current Report Filed: 2026-01-09

Key Insights

Atossa Therapeutics reported an estimated cash and cash equivalents balance of approximately $40 million as of December 31, 2025, indicating a strong financial position.
The company provided an updated corporate presentation, suggesting ongoing progress in its development and regulatory strategy for its lead program, (Z)-Endoxifen.
Atossa Therapeutics mentioned the potential for (Z)-Endoxifen to receive regulatory approval, though the timing and specific indications were not disclosed.

Current Report Filed: 2026-01-06

Key Insights

The company has received a 'Study May Proceed' letter from the FDA for a study of metastatic breast cancer, indicating regulatory progress for a key pipeline asset.
The press release announcement on this regulatory milestone suggests the company is making advancements in its clinical development program.
Investors should monitor further updates on the progress and timeline of this breast cancer study, as it could be an important value driver for the company.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information